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Abstract 
Background: Urinary tract infection (UTI) is a common reason for antimicrobial prescription in dogs and cats. The 
objective of this study was to optimize and evaluate a culture-based point-of-care test for detection, identification 
and antimicrobial susceptibility testing of bacterial uro-pathogens in veterinary practice.
Methods: Seventy-two urine samples from dogs and cats with suspected UTI presenting to seven veterinary facilities 
were used by clinical staff and an investigator to estimate sensitivity and specificity of Flexicult Vet A compared to 
laboratory reference standards for culture and susceptibility testing. Subsequently, the test was modified by inclu-
sion of an oxacillin-containing compartment for detection of methicillin-resistant staphylococci. The performance of 
the modified product (Flexicult Vet B) for susceptibility testing was evaluated in vitro using a collection of 110 clinical 
isolates.
Results: Bacteriuria was reported by the laboratory in 25 (35 %) samples from the field study. The sensitivity and 
specificity of Flexicult Vet A for detection of bacteriuria were 83 and 100 %, respectively. Bacterial species were cor-
rectly identified in 53 and 100 % of the positive samples by clinical staff and the investigator, respectively. The suscep-
tibility results were interpreted correctly by clinical staff for 70 % of the 94 drug-strain combinations. Higher percent-
ages of correct interpretation were observed when the results were interpreted by the investigator in both the field 
(76 %) and the in vitro study (94 %). The most frequent errors were false resistance to β-lactams (ampicillin, amoxi-
cillin-clavulanate and cephalotin) in Escherichia coli for Flexicult Vet A, and false amoxicillin-clavulanate resistance in 
E. coli and false ampicillin susceptibility in Staphylococcus pseudintermedius for Flexicult Vet B. The latter error can be 
prevented by categorizing staphylococcal strains growing in the oxacillin compartment as resistant to all β-lactams.
Conclusions: Despite the shortcomings regarding species identification by clinical staff and β-lactam susceptibil-
ity testing of E. coli, Flexicult Vet B (commercial name Flexicult® Vet) is a time- and cost-effective point-of-care test 
to guide antimicrobial choice and facilitate implementation of antimicrobial use guidelines for treatment of UTIs in 
small animals, provided that clinical staff is adequately trained to interpret the results and that clinics meet minimum 
standards to operate in-house culture.
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Background
Urinary tract infection (UTI) is a common reason for anti-
microbial prescription in small animal veterinary practice. 
It has been estimated that 14 % of all dogs are diagnosed 
with bacterial UTI during their lifetime [1]. UTI is less 
frequent and usually associated with comorbidities in 
cats [2]. Escherichia coli is by far the most frequent spe-
cies involved in at least 50  % of canine and feline UTIs 
[2, 3]. Other relatively common species include Staphy-
lococcus spp., Enterococcus spp., Proteus spp., Klebsiella 
spp., Pseudomonas spp., and Streptococcus spp. [3–5]. The 
diagnosis is based on clinical signs, urinalysis and quan-
titative microbiology. Empirical antimicrobial therapy is 
frequent, especially in first-time uncomplicated UTIs. 
According to international and Danish guidelines for anti-
microbial use in companion animals [6, 7], urine samples 
from small animals with suspected UTI should be sub-
jected to culture and susceptibility testing when treating 
with antibiotics. However, several factors influence nega-
tively implementation of this recommendation in veteri-
nary practice, i.e. long laboratory turnaround time, special 
requirements for shipping (i.e. urine samples should be 
refrigerated if they cannot be processed within 24 h after 
collection), and economic costs for pet owners. In-house 
culture is a possible alternative to laboratory analysis but 
not all clinics are equipped to perform bacterial isola-
tion and antimicrobial susceptibility testing according to 
international quality and biosafety standards. Even if per-
formed optimally, in-house diagnostic culture requires at 
least 2 days before treatment can be initiated or adjusted 
based on antimicrobial susceptibility results.
Point-of-care testing is a possible approach to reduce 
both turnaround time and costs. Flexicult™ (SSI Diagnos-
tica, Hillerød, Denmark) is a diagnostic product widely 
used in Denmark for point-of-care diagnosis and suscep-
tibility testing of uncomplicated urinary tract infections 
(UTIs) in human primary health care [8]. The test allows 
(1) semi-quantitative enumeration of bacteria in urine, (2) 
presumptive identification of uropathogens and (3) pre-
diction of antimicrobial susceptibility of uropathogens. A 
veterinary derivative product (Flexicult® Vet), hereinaf-
ter referred to as Flexicult Vet A, was first launched in the 
US in December 2010. The agar content of the product for 
human use was modified to enhance growth of veterinary 
pathogens including Staphylococcus pseudintermedius and 
Streptococcus canis, which grow poorly on Flexicult™ plates 
for human use. The objective of this study was to optimize 
and evaluate this point-of-care test for use in small animal 
practice. On-site performance of Flexicult Vet A was evalu-
ated by a field trial conducted in seven small animal veteri-
nary clinics in Denmark. Subsequently the composition of 
the antimicrobial panel was optimized to enable detection 
of methicillin-resistant S. pseudintermedius (MRSP), which 
are multidrug-resistant bacteria of high concern in small 
animal veterinary practice [9]. The modified test, herein-
after referred to as Flexicult Vet B, was evaluated in vitro 
using a strain collection representative of all major bacterial 
species implicated in canine and feline UTIs.
Methods
Description of Flexicult Vet A
Flexicult Vet A consists of a plastic Petri dish divided 
into one large compartment containing a non-selective 
growth medium (Mueller–Hinton BBL-II agar, Bec-
ton–Dickinson, Basel, Switzerland) supplemented with 
a chromogenic mixture, and five smaller compartments 
with the same medium supplemented with ampicillin 
(16 µg/ml), amoxicillin-clavulanate (12/6 µg/ml), cepha-
lotin (12 µg/ml), enrofloxacin (0.5 µg/ml), and sulfameth-
oxazole-trimethoprim (38/2 µg/ml), respectively (Fig. 1). 
After flooding the plate with urine for 1–2 s, the excess 
of urine is discarded and the plate is incubated bottom-
up at 35–37  °C for 24  h before reading. Bacterial loads 
are estimated by visual examination of colony density in 
the large compartment (Fig.  2), and strain susceptibility 
is deduced by growth in the smaller compartments con-
taining antimicrobial concentrations based on Clinical 
Laboratory Standards Institute (CLSI) breakpoints [10]. 
As a secondary feature, the agar contains a chromogenic 
Fig. 1 Description of Flexicult® Vet. Flexicult® Vet (Flexicult Vet B in 
the text) is a point-of-care test allowing (a) semi-quantitative enumer-
ation of bacteria in urine, (b) presumptive identification of uropatho-
gens, and (c) prediction of antibiotic susceptibility of uropathogens. 
The test consists of a plastic Petri dish divided into five smaller 
compartments for susceptibility testing of ampicillin (1), amoxicillin-
clavulanate (2), oxacillin (3), enrofloxacin (4), and sulfamethoxazole-tri-
methoprim (5), and one large compartment containing non-selective 
growth medium for semi-quantitative bacterial enumeration (6)
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substrate to facilitate bacterial identification, as colonies 
display different colours depending on the bacterial spe-
cies (Fig. 3).
Field trial
Seven small animal veterinary clinics in Denmark, 
including one tertiary facility (The University Hospital 
Fig. 2 Semi-quantitative bacterial enumeration by Flexicult® Vet. Growth of Escherichia coli at different concentrations: 103 CFU/ml (a), 104 CFU/ml 
(b) and 105 CFU/ml (c). The strain is susceptible to all antimicrobial agents tested except oxacillin
Fig. 3 Bacterial identification by Flexicult® Vet. The Flexicult® Vet agar contains a chromogenic substrate to enhance bacterial identification, as 
colonies display different colors depending on the bacterial species. Examples of common pathogens involved in canine and feline UTI: Escherichia 
coli (a), Staphylococcus pseudintermedius (b), Proteus mirabilis (c), and Enterococcus faecalis (d)
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for Companion Animals), one secondary facility (private 
referral hospital), and five smaller primary facilities par-
ticipated in the study. Dogs and cats visiting these clin-
ics between March and July 2013 were considered eligible 
for inclusion in the study when urine culture was part of 
their diagnostic work up. The clinics were supplied with 
Flexicult Vet A plates and incubators for in house testing, 
and the clinical staff members were instructed orally and 
in writing on how to use and interpret the test accord-
ing to the manufacturer’s instructions. A portion of the 
urine samples was used by the clinical staff for in-house 
testing by Flexicult Vet A, and the remaining urine was 
submitted in sterile containers to the veterinary diagnos-
tic microbiology laboratory at University of Copenhagen 
(Sund Vet Diagnostik, http://sundvetdiagnostik.ku.dk) or 
cultured overnight on Uricult® dipslides (Orion Diagnos-
tica, Nivå, Denmark) prior to submission to the labora-
tory. For each sample, the clinical staff member recorded 
the results obtained by Flexicult Vet A, including growth, 
bacterial concentration (CFU/ml), growth in the five 
antimicrobial compartments and bacterial identification. 
Data were also recorded about when and how the urine 
sample was collected (cystocentesis, urinary catheter or 
midstream catch), when the Flexicult Vet A plates were 
incubated and read, and who read them. Moreover, the 
clinical staff was asked to take pictures of the plates after 
incubation and to send them electronically to one of the 
investigators (SH) for interpretation.
At the diagnostic laboratory, ten µl of urine were cul-
tured overnight at 37  °C on 5  % bovine blood agar for 
quantitative microbiology. Free catch samples were 
scored as positive (i.e. clinically relevant bacteriuria) on 
blood agar and on Flexicult Vet A if they contained ≥105 
CFU/ml, whereas the thresholds for urine collected by 
cystocentesis and catheter were ≥103 and ≥104, respec-
tively. Isolates displaying distinct colony morphology 
were identified to the species level by MALDI-TOF mass 
spectrometry (MS) (VITEK® MS, bioMérieux, Marcy 
l’Etoile, France), and their antimicrobial susceptibil-
ity profile was determined by broth microdilution using 
Sensititre® COMPAN1F plates (Trek Diagnostic Sys-
tems, part of Thermo Fisher Scientific, East Grinstead, 
UK) according to CLSI [10]. The results of culture and 
susceptibility testing at the diagnostic laboratory were 
compared to those recorded by clinical staff and by the 
investigator using Flexicult Vet A.
Optimization of antimicrobial panel
The composition of the antimicrobial panel of Flexicult 
Vet A was changed by replacing cephalotin with oxacillin 
for detection of MRSP. To optimize oxacillin concentra-
tion, plates containing the agar base supplemented with 
twofold dilutions of oxacillin (0.062–0.5  µg/ml) with or 
without 2 % NaCl were tested using 15 clinical MRSP iso-
lates belonging to 10 multi-locus sequence types, and 15 
randomly selected clinical S. pseudintermedius isolates 
susceptible to methicillin. Forty µl of bacterial suspen-
sions containing 103 and 104 CFU/ml were spread on a 
quarter of each plate followed by incubation at 37  °C. 
Plates were read after 24 and 48  h. This work resulted 
in a new version of the product (Flexicult Vet B) with a 
compartment containing 0.125 ug/ml of oxacillin and 2 % 
NaCl.
In vitro validation of Flexicult Vet B
The performance of Flexicult Vet B for susceptibility test-
ing was validated in vitro using a collection of 110 clini-
cal isolates identified to the species level by MALDI-TOF 
MS. The collection included 40 E. coli, 20 S. pseudinter-
medius (including 10 MRSP belonging to multi-locus 
sequence types ST71, ST267, ST269, ST270, ST271, 
ST272 and ST273), 12 Proteus mirabilis, 10 Streptococ-
cus canis, 7 Enterococcus faecalis, 5 S. aureus (including 
2 MRSA belonging to ST22 and ST239), 5 Enterococ-
cus faecium, 4 Enterobacter cloacae, 3 Pantoea agglom-
erans, 2 Klebsiella pneumoniae, 1 Klebsiella oxytoca, 
and  1 Enterobacter aerogenes. Nine E. coli isolates were 
extended-spectrum β-lactamase (ESBL) producers with 
known genetic background: five producing CTX-M, 
two producing CMY and two producing both types of 
enzyme. These strains were included due to the clinical 
relevance of ESBL-producers in UTIs [6].
For each isolate, colonies from an overnight culture on 
5 % bovine blood agar were suspended in saline to a tur-
bidity of 0.5 McFarland (~108 CFU/ml). The suspension 
was diluted to concentrations of approximately 103 and 
104 CFU per ml. From each dilution, 300  µl was trans-
ferred to the large compartment of the Flexicult Vet B 
plate, and 100 µl to each of the small antimicrobial com-
partments, followed by gently tilting the plate and dis-
carding excess fluid. Plates were read following overnight 
incubation at 35 °C. Strains growing in the antimicrobial 
compartments were regarded as resistant and their sus-
ceptibility profiles obtained by Flexicult Vet B were com-
pared to those previously determined at the diagnostic 
laboratory by broth microdilution using the methodology 
described above [10].
Statistical analysis
In the field trial, sensitivity and specificity of Flexicult 
Vet A for detection of clinically-relevant bacteriuria and 
for detection of resistance to the five drugs included in 
the test were estimated using laboratory culture on blood 
agar and MIC testing by broth micro-dilution as the refer-
ence standards, respectively. The performance of the test 
was evaluated according to the interpretations made by 
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clinical staff and by the investigator. Sensitivity and speci-
ficity of the test for susceptibility testing were calculated 
by a 2 ×  2 table using resistance (R) as a positive result 
(+) and susceptibility S as a negative (−) result. The Fisher 
exact test was used to evaluate whether clinically relevant 
bacteriuria detected by the reference standard was influ-
enced by the method used for urine collection or by the 
time elapsed between sample collection and laboratory 
analysis. In the in  vitro study, sensitivity and specificity 
of Flexicult Vet B for antimicrobial susceptibility testing 
were determined as described for the field trial.
Results
Field trial
A total of 72 urine samples were collected from 56 
patients, including 42 (75 %) dogs and 14 (25 %) cats. For 
13 patients (2 cats and 11 dogs) samples were collected 
in two or three occasions upon repeated admission of 
patients. For nine samples, Uricult® dip slides were sub-
mitted to the laboratory after overnight culture. The 
remaining 63 samples were received and processed at the 
laboratory either on the day of collection (n =  47), the 
day after (n = 13), or two days after (n = 3). The major-
ity of samples (61/72) were collected by cystocentesis, six 
by free catch and two by catheter. For three samples the 
sampling method was not reported.
Of the 72 samples, 25 (35  %) were culture-positive 
according to conventional culture in the diagnostic labo-
ratory. Results from two of the culture-positive samples 
were excluded from further analyses because of failure of 
the diagnostic laboratory to report bacterial counts. The 
sensitivity (83  %, CI 0.63–0.93) and specificity (100  %, 
CI 0.92–1.00) of Flexicult Vet A for detection of clini-
cally-relevant bacteriuria were the same regardless if the 
results were interpreted by clinical staff or by the investi-
gator. Four false negative results were recorded by both 
the clinical staff and the investigator (Table 1). According 
to conventional culture, these samples were culture-
positive with high bacterial concentrations (≥105 CFU/
ml), whereas on Flexicult Vet A two (positive for E. coli 
and S. canis by conventional culture) were sterile and the 
other two (positive for P. mirabilis and E. faecium by con-
ventional culture) displayed bacterial growth below the 
defined threshold.
Urine specimens collected by cystocentesis were more 
frequently culture-negative (68  %) compared to those 
collected by other methods (57 %) (Fisher exact test, one-
tailed, P = 0.41). Among the 19 samples culture-positive 
by both conventional culture and Flexicult Vet A, two 
were excluded for evaluation of species identification 
due to failure of clinical staff to provide interpretation of 
species on Flexicult Vet A plates. Conventional culture 
of the remaining 17 samples resulted in growth of E. coli 
(n = 11), K. pneumoniae (n = 2), P. mirabilis (n = 1), E. 
faecalis (n = 1), Pseudomonas aeruginosa (n = 1) and S. 
pseudintermedius (n  =  1). Clinical staff identified cor-
rectly the bacterial species in 9 (53  %, CI 0.31–0.74) 
samples. Identification mistakes occurred for all genera 
except Enterococcus. The investigator identified correctly 
the species in all the samples (100 %, CI 0.78–1.00).
The performance of Flexicult Vet A for susceptibil-
ity testing was evaluated using the laboratory results 
obtained by broth microdilution as the reference stand-
ard. False susceptibility was not observed for any of the 
19 culture-positive samples for which the interpretations 
by clinical staff were available. The susceptibility results 
were correct for 70 and 76 % of the 94 drug-strain combi-
nations tested when the results were interpreted by clini-
cal staff and the investigator, respectively. The test was 
able to correctly detect all the strains that were resist-
ant according to the reference standard method (100  % 
sensitivity, CI 0.72–1.00) but not all the strains that 
were susceptible [67 % specificity according to the clini-
cians’ interpretations (CI 0.56–0.76) and 73 % specificity 
according to the investigator’s interpretation (CI 0.62–
0.82)]. False resistance to β-lactams (ampicillin, amoxicil-
lin-clavulanate and cephalotin) was frequent, especially 
among E. coli isolates (Table 2).
Development and in vitro validation of Flexicult Vet B
Table  3 shows how MRSP detection was influenced by 
oxacillin concentration and presence of 2 % NaCl. Results 
were not affected by the inoculum size (103 or 104 CFU/
ml). Inclusion of 0.125 µg/ml of oxacillin and 2 % NaCl 
in the Flexicult Vet B agar base resulted in the most reli-
able MRSP detection (100  % sensitivity and specificity) 
(Table 3).
The susceptibility results were correct for 94  % of the 
465 drug-strain combinations tested by Flexicult Vet 
B (Table  4). The overall sensitivity (i.e. test’s ability to 
Table 1 Detection of clinically relevant bacteriuria by Flex-
icult Vet A in 70 urine samples from dogs or cats
The interpretations by clinical staff and by the investigator are compared to 
the laboratory results obtained by aerobic culture on blood agar (reference 
standard)





 Positive 19 0 19
 Negative 4 47 51
 Total 23 47 70
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correctly detect resistant strains) and specificity (i.e. 
test’s ability to correctly detect susceptible strains) for 
antimicrobial susceptibility were 89  % (CI 0.83–0.94) 
and 96  % (CI 0.93–0.98), respectively. Eighty-seven 
(79  %) of the 110 strains’ susceptibility profiles were 
in full accordance with results from MIC determina-
tion by broth microdilution (gold standard). The overall 
error rate for the 465 antimicrobial-strain combinations 
tested was 6  % (Table  4). The most frequent error was 
false amoxicillin-clavulanate resistance in 12 of the 63 
(19  %) Enterobacteriaceae isolates, including 10 E. coli 
(MIC = 8/4 µg/ml), four of which producing ESBL of the 
CTX-M type, one P. mirabilis (MIC = 8/4 µg/ml) and one 
E. cloacae (MIC ≤ 4/2 µg/ml). The second most common 
error was false ampicillin susceptibility in 3 of the 20 
(15 %) S. pseudintermedius isolates. These three isolates 
were MRSP and had ampicillin MICs of 16 µg/ml (n = 1) 
and > 16 µg/ml (n = 2). Overall, only a single error was 
observed for enrofloxacin (false resistant Proteus) and for 
sulfamethoxazole with trimethoprim (false susceptible 
Table 2 Antimicrobial susceptibility of Escherichia coli and other bacterial species in 19 culture-positive urine samples
The interpretations of Flexicult Vet A by clinical staff and by the investigator are compared to the laboratory results obtained by broth microdilution (reference 
standard). A slash line is used to separate the results obtained by clinical staff (on the left) when they differed from those by the investigator (on the right)
AMP ampicillin, AMC amoxicillin-clavulanate, CEF cephalotin, ENR enrofloxacin, SXT trimethoprim-sulfamethoxazole
a Other species: Proteus mirabilis (n = 2), Staphylococcus pseudintermedius (n = 1), Enterococcus faecalis (n = 1), Klebsiella pneumoniae (n = 2), and Pseudomonas 
aeruginosa spp. (n = 1)
b Cefazolin was used instead of cephalotin for testing susceptibility to 1st generation cephalosporins by the reference standard method
c One Enterococcus isolate intermediate to enrofloxacin according to the reference standard was not included in the analysis of enrofloxacin susceptibility
d The values 8 and 4 represent amoxicillin and clavulanate, respectively
e The values 2 and 38 represent trimethoprim and sulfamethoxazole, respectively
Flexicult Vet A Reference standard
AMP (R > 8 µg/ml) AMC (R > 8/4d µg/ml) CEFb (R > 4 µg/ml) ENRc (R > 2 µg/ml) SXT (R > 2/38e 
µg/ml)
R S R S R S R S R S
E. coli (n = 12)
 R 2 8/7 0 9 0 8/7 0 0 0 0
 S 0 2/3 0 3 0 4/5 0 12 0 12
Other (n = 7)a
 R 3 0 1 1/0 2 1/0 0 1/0 2 0
 S 0 4 0 5/6 0 4/5 0 5/6 0 5
Table 3 Growth of  15 methicillin-resistant (MRSP) and  15 methicillin-susceptible Staphylococcus pseudintermedius 
(MSSP) strains on  Flexicult Vet agar base supplemented with  different oxacillin concentrations (µg/ml) in  the presence 
(+) or absence (–) of 2 % NaCl
The results are presented as the proportions of correctly classified MRSP (growth) and MSSP (no growth) isolates following 24 and 48 h of incubation
a The same result was recorded after 24 and 48 h of incubation
b 0.125 µg/ml oxacillin + 2 % NaCl was selected for Flexicult Vet B replacing the cephalotin compartment in Flexicult Vet A




0.5 – 24/48a 7/15 0/15
+ 24 9/15 0/15
+ 48 10/15 0/15
0.25 – 24/48a 10/15 0/15
+ 24 10/15 0/15
+ 48 11/15 0/15
0.125b – 24/48a 13/15 0/15
+ 24/48a 15/15 0/15
0.062 – 24/48a 15/15 15/15
+ 24/48a 15/15 15/15
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Enterococcus). Oxacillin susceptibility was correctly clas-
sified for all the 20 S. pseudintermedius tested, whereas 
one of the five S. aureus isolates was false resistant 
(Table 4). S. aureus and S. pseudintermedius were indis-
tinguishable on Flexicult Vet B after 24 h incubation but 
after 48  h S. pseudintermedius colonies became pinkish 
with variable colour intensity among the strains, whereas 
S. aureus colonies remained uncoloured (Fig. 4).
Discussion
Rational antimicrobial use is a key element for control 
of antimicrobial resistance. Currently, various measures 
are being taken at the national, European and global 
level to reduce antimicrobial consumption in animals, 
including companion animals. Veterinary clinicians have 
the responsibility to implement these measures with-
out impacting animal welfare. To enhance effective and 
sustainable implementation of rational antimicrobial 
use for treatment of UTIs, rapid and reliable point-of-
care tests are needed to ensure that i) antimicrobials are 
prescribed/used only when necessary, and ii) the most 
appropriate drug is chosen taking into consideration the 
antimicrobial resistance profile of the causative strain. 
Our results show that the final product developed by 
this study (commercial name Flexicult® Vet) is a useful 
point-of-care test to guide antimicrobial therapy of UTIs 
in small animals. The test provides overnight information 
on the presence of bacteria in urine and indicates which 
drug is appropriate for therapy. As such, it can be used 
to reduce empirical antimicrobial use and avoid unneces-
sary therapy. Compared to urine dipstick slides, it has the 
additional advantage of providing information on antimi-
crobial susceptibility. This is particularly important when 
resistance to the first tier drugs recommended by local 
or national antimicrobial guidelines is not infrequent. 
For example, amoxicillin is generally regarded as a first 
tier antimicrobial for treatment of uncomplicated lower 
UTIs in dogs and cats but resistance is relatively common 
in E. coli and other bacterial species isolated from these 
infections. In Denmark and Sweden, the prevalence of 
resistance to aminopenicillins (i.e. ampicillin and amoxi-
cillin) in clinical E. coli isolates ranged from 16–26 % in 
Table 4 Comparison of the antimicrobial susceptibility results obtained for 105 clinical isolates by Flexicult Vet B and by 
the broth microdilution method (reference standard)
AMP ampicillin, AMC amoxicillin-clavulanate, OXA oxacillin, ENR enrofloxacin, SXT trimethoprim-sulfamethoxazole
a Oxacillin results were only interpreted for S. pseudintermedius and S. aureus, since this drug is a surrogate drug for detection of methicillin resistance in staphylococci
b The values 8 and 4 represent amoxicillin and clavulanate, respectively
c The values 2 and 38 represent trimethoprim and sulfamethoxazole, respectively















R S R S R S R S R S
Escherichia coli (n = 40) R 22 – 5 – 13 – 18 –
S – 18 10 25 – 27 – 22
Staphylococcus pseudintermedius (n = 20) R 3 3 1 2 10 – 5 – 8 –
S – 14 – 17 – 10 – 15 – 12
Proteus mirabilis (n = 12) R 4 – 1 2 1 – 2 –
S – 8 1 8 1 10 – 10
Enterococcus spp. (n = 12) R 2 2 2 2 8 – 2 1
S – 8 – 8 – 4 – 9
Streptococcus canis (n = 10) R – – – – 1 – – –
S – 10 – 10 – 9 – 10
Enterobacter spp. (n = 8) R 3 – 4 – – – – –
S 1 4 1 3 – 8 – 8
Staphylococcus R 1 – 1 – 2 – 2 – 1 –
aureus (n = 5) S – 4 – 4 1 2 – 3 – 4
Klebsiella spp. (n = 3) R 2 1 – – – – – –
S – – – 3 – 3 – 3
Total (n = 105) R 37 6 14 6 12 – 30 – 31 1
S 1 66 12 78 1 12 1 79 – 78
Page 8 of 10Guardabassi et al. Acta Vet Scand  (2015) 57:72 
2011–2012 [7]. Thus, use of Flexicult® Vet could poten-
tially avoid prescription of amoxicillin for a large num-
ber of patients infected with strains resistant to this 
antibiotic.
The results of this study show good sensitivity and 
specificity of Flexicult® Vet for both detection of clini-
cally relevant bacteriuria and antimicrobial susceptibility 
testing. The results were generally concordant between 
clinical staff and the investigator, and between the inves-
tigator and the clinical microbiology laboratory (Tables 1, 
2). Two notable exceptions were detected in the in vitro 
study: false amoxicillin-clavulanate resistance in Entero-
bacteriaceae and false ampicillin susceptibility in MRSP. 
These two errors should be regarded as major and very 
major errors, respectively [11]. A “major error” occurs 
when the new test indicates resistance in a strain that is 
categorized as susceptible by the reference method. This 
error reduces the range of antimicrobial options available 
to the clinician and may lead to unnecessary use of broad-
spectrum drugs, with potential negative consequences on 
selection of resistance. A “very major error” occurs when 
a strain categorized as resistant by the reference method 
is reported as susceptible by the test. This type of error 
has a greater impact on patient care, since the clinician 
may choose a drug that is unlikely to be effective against 
the strain causing infection, with all the negative conse-
quences of treatment failure. Based on this classification, 
false ampicillin susceptibility in MRSP appears to be the 
most important problem of the test. However, this error 
was solved by the inclusion of oxacillin in the test, since 
all the isolates displaying false ampicillin susceptibility 
were resistant to oxacillin and should be categorized as 
Fig. 4 Colony appearance of Staphylococcus pseudintermedius and Staphylococcus aureus on Flexicult® Vet plates. The two species are distinguish-
able after 48 h incubation since Staphylococcus pseudintermedius colonies are pinkish with a colour of variable intensity depending on the strain (a, 
b), whereas Staphylococcus aureus remained white/yellow (c, d)
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resistant to all veterinary β-lactams according to inter-
national standards [10]. Thus, this error is irrelevant if 
clinical staff is trained to identify staphylococcal strains 
and interpret the oxacillin susceptibility result correctly. 
It should be noted that the oxacillin concentration was 
chosen based on the clinical breakpoint for S. pseud-
intermedius (R  ≥  0.5  µg/ml), which is eightfold lower 
than for S. aureus (R ≥ 4 µg/ml) [10]. This explains why 
false oxacillin resistance was detected in one methicillin-
susceptible S. aureus (Table 4). As the colony appearance 
becomes distinguishable between the two species after 
48 h incubation (Fig. 4), we recommend that incubation 
of Flexicult® plates is extended to 48  h when suspected 
staphylococcal colonies are detected in the oxacillin 
compartment. Moreover, as a matter of principle, pre-
sumptive MRSP and MRSA should be confirmed and 
subjected to antimicrobial susceptibility testing by a diag-
nostic laboratory to guide antimicrobial choice.
In relation to the false amoxicillin-clavulanate resist-
ance observed in Enterobacteriaceae, it should be noted 
that the MIC of amoxicillin-clavulanate (8/4 µg/ml) was 
just below the clinical breakpoint (R > 8/4 µg/ml) in nine 
out of the 10 false resistant isolates, and five of them were 
CTX-M-producing E. coli. Some studies in human medi-
cine suggest that amoxicillin-clavulanate might be con-
sidered as a second-line agent for management of lower 
UTI caused by ESBL producers with even higher MIC 
than that observed in these isolates [12]. Clinical cure is 
likely due to the high drug concentrations achieved in 
urine and the theoretical inactivation of ESBLs by cla-
vulanate. However this is a controversial issue and nei-
ther retrospective nor prospective studies have been 
performed to provide evidence of clinical cure in small 
animals. We recommend that Flexicult® Vet plates are 
submitted to a diagnostic laboratory and specialist advice 
is sought when growth is observed in all the five anti-
microbial compartments. Furthermore, instructions to 
users should be made available online to reduce the risk 
of errors in the interpretation of the antimicrobial sus-
ceptibility results, for example by providing detailed 
guidelines on how to interpret growth of one or few colo-
nies in one of the antimicrobial-containing fields.
In the field study, pathogen identification by clinical 
staff was unreliable, since the species was correctly iden-
tified in only 53 % of the culture-positive samples. Simi-
lar findings have been reported for dipstick slides in both 
human and veterinary settings [13–15]. Although patho-
gen identification may be regarded as a secondary feature 
of the test as it provides information of limited clinical 
relevance, particular attention should be given to avoid 
certain errors that may lead to inappropriate antimicro-
bial choice. For example, misidentification of staphylo-
cocci may cause erroneous prescription of β-lactams for 
treatment of MRSP and MRSA UTIs despite growth in 
the oxacillin compartment, which is indicative of resist-
ance to all β-lactams for this bacterial group. Our study 
shows that the charts provided by the manufacturer may 
not be sufficient to avoid frequent errors in pathogen 
identification. Importantly, our results also show that 
interpretation can be improved significantly with expe-
rience, as indicated by the excellent score obtained by 
the investigator. Accordingly, the authors recommend 
that training sessions are offered by the manufacturer to 
enhance correct interpretation of the results, including 
examples of mixed cultures, which make identification 
more difficult compared to pure bacterial cultures. Users 
are also recommended to validate their interpretive skills 
by sending plates regularly to a diagnostic laboratory for 
species identification.
Notably, the use of true urine samples instead of pure 
cultures suspended in saline seems also to reduce the 
performance of the test for antimicrobial susceptibil-
ity testing under real-life conditions, as indicated by the 
lower specificity estimated in the field study (73 %) com-
pared to the in  vitro study (95  %) based on the investi-
gator’s interpretations. This discrepancy was largely due 
to high rate of false resistance to β-lactams observed for 
E. coli in the field study. The reason for this discrepancy 
remains unknown but it appears that urine may interfere 
with the results of β-lactam susceptibility testing as this 
problem was not observed when the plates were inocu-
lated with bacterial suspensions in sterile saline in the 
in vitro study.
Due to the circumstances described in the results sec-
tion, only 17 and 19 culture-positive samples were evalu-
ated for bacterial species identification and antimicrobial 
susceptibility testing in the field trial, respectively. This is 
a major limitation of the study, since the performance of 
a point-of-care test like this should primarily be evalu-
ated based on the results obtained by clinical staff using 
urine samples. Thus, further studies are warranted to 
evaluate the performance of the test in the field. The 
high (65  %) proportion of culture-negative samples in 
the field trial may in part be explained by the participa-
tion of tertiary and secondary facilities in the study and 
by the inclusion criteria being any indication for culture, 
thus not restricted to patients displaying symptoms of 
UTI. An even lower percentage of 17.5 % positivity was 
recently reported among 5923 urine samples cultured in 
a UK tertiary referral hospital between 1999 and 2009 
[16]. Culture-negative results are particularly common 
when screening animals with low urinary specific grav-
ity for UTI [17], and for samples collected by cystocen-
tesis [15], as most samples (61/72) used in this study. The 
uncertainty of bacterial infection and the consequent risk 
of antimicrobial overuse in patients with suspected UTI 
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highlight the usefulness of point-of-care tests allowing 
clinicians to take evidence-based decisions on whether 
antimicrobial therapy is needed. However, responsible 
use of culture-based point-of-care tests requires trained 
staff and adequate laboratory facilities and waste man-
agement procedures.
Conclusions
Flexicult® Vet is a time- and cost-effective point-of-care 
test for detection of bacteriuria and antimicrobial sus-
ceptibility testing of uropathogens in small animal vet-
erinary clinics that meet the minimal requirements for 
in-house culture. Even though we identified important 
shortcomings regarding species identification by clinical 
staff and β-lactam susceptibility testing of E. coli, rational 
use of this product may guide antimicrobial choice and 
facilitate implementation of the current antimicrobial use 
guidelines for treatment of UTIs. Following this study the 
manufacturer has revised instruction manuals illustrat-
ing interpretation of bacterial counts and species. Apart 
from this initiative we recommend adequate training of 
clinicians to reduce the risk of interpretative errors of 
potential impact on patient care, such as those regarding 
staphylococcal identification and growth in the oxacillin-
containing compartment.
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